natgillin/translations-raw huggingface dataset:
The clear plastic liner covering the adhesive should be removed and discarded with care taken not to touch the gels.
Prozorno plastično folijo, ki prekriva samolepilni del, je treba odstraniti in zavreči ter pri tem paziti, da se ne dotaknete gela.
The IONSYS system should be pressed firmly in place with the sticky side down on the skin for at least 15 seconds.
Sistem IONSYS je treba trdno pritisniti na kožo za najmanj 15 sekund, z lepljivo stranjo obrnjeno navzdol.
Pressure should be applied with the fingers around the outer edges to ensure adhesion to the skin site for the full 24-hour wearing period.
S prsti pritiskajte vzdolž zunanjega roba sistema, da bi zagotovili dobro prileganje na kožo v celotnem 24- urnem obdobju uporabe.
Occasionally, the IONSYS system may loosen; if this occurs a non-allergenic tape may be used to be sure all of the system’ s edges make complete contact with the skin.
Če se to zgodi, lahko uporabite samolepilni trak, ki ne povzroča alergij, da bodo vsi robovi sistema zagotovo dobro prilepljeni na kožo.
Care should be taken not to press or tape over the button or red light.
Paziti je treba, ne boste pritisnili na odmerni gumb ali na rdečo lučko ali ju prelepili.
3 Dose Delivery
3 Sproščanje odmerkov
A recessed on-demand dosing button and red light are located on the top housing of the IONSYS system.
Na zgornjem delu ohišja sistema IONSYS se nahajata vdrt odmerni gumb za odmerjanje na zahtevo in rdeča lučka.
To initiate administration of a fentanyl dose, the patient should press the on-demand button twice within 3 seconds.
Če želi sprožiti sproščanje odmerka fentanila, naj bolnik pritisne na gumb za odmerjanje na zahtevo dvakrat v času 3 sekund.
IONSYS should only be activated by the patient.
Sistem IONSYS sme aktivirati le sam bolnik.
A beep indicates the start of delivery of the dose; the red light remains on throughout the 10-minute dosing interval.
Pisk bo označil začetek sproščanja odmerka in rdeča lučka bo prižgana ves čas 10- minutnega intervala odmerjanja.
The next dose cannot be initiated until the previous 10-minute delivery cycle is complete.
Bolnik ne bo mogel sprožiti sproščanja naslednjega odmerka, dokler ne bo zaključen prejšnji 10 - minutni ciklus odmerjanja.
Pressing the button during delivery of a dose will not result in additional medicinal product being administered.
S pritiskom na gumb med sproščanjem posameznega odmerka bolnik torej ne bo povzročil sproščanja dodatnega zdravila.
The red light turns off after the 10-minute dose has been delivered.
Rdeča lučka bo ugasnila, ko bo zaključeno 10- minutno sproščanje odmerka.
Determining Approximate Number of Doses Delivered
Določitev približnega števila sproščenih odmerkov
Between doses, the red light will blink in one-second pulses to indicate the approximate number of doses administered up to the present time.
Med posameznimi odmerki bo rdeča lučka utripala v enosekundnih pulzih in s tem kazala približno število do tedaj sproščenih odmerkov.
Each one-second pulse of light indicates administration of up to five doses.
Vsak enosekundni svetlobni pulz pomeni do pet sproščenih odmerkov.
Thus, a single one-second pulse of light represents 1 to 5 doses; two pulses represent 6-10 doses; three pulses represent 11-15 doses; up to 16 pulses which represents 76-80 doses delivered.
Torej pomeni en enosekundni svetlobni pulz 1 do 5 odmerkov, dva pulza pomenita 6 do 10 odmerkov, trije pulzi 11 do 15 odmerkov, vse do 16 pulzov, ki pomenijo 76 do 80 sproščenih odmerkov.
The system may also be queried during delivery of an on-demand dose by pressing the button once.
Število odmerkov lahko tudi preverite med dajanjem odmerka na zahtevo, in sicer tako, da enkrat pritisnete na gumb.
The red LED will pulse as outlined above to indicate the approximate number of on-demand doses delivered up to the query.
Rdeča LED bo pulzirala, kakor je opisano zgoraj, in tako kazala približno število odmerkov na zahtevo, sproščenih do trenutka preverjanja.
This query will not influence dose delivery.
Preverjanje števila odmerkov ne bo vplivalo na sproščanje odmerka.
Removal
Odstranjevanje sistema
IONSYS may be removed at any time.
Sistem IONSYS lahko odstranite kadarkoli.
However, once a system has been removed, the same system should not be reapplied.
Ko pa ste ga enkrat sneli s kože, ga ne smete več uporabiti.
At the end of 24 hours of use or after 80 doses have been delivered, remove the IONSYS system by gently lifting the red tab and loosening the system from the skin application site.
Ob koncu 24- urne uporabe ali po 80 sproščenih odmerkih zdravila snemite sistem IONSYS tako, da previdno potegnete za rdeč trak in odlepite sistem s kože.
If the patient requires additional or continuation of pain relief, a new system may be applied to a new skin site on the upper outer arm or chest.
Če bolnik potrebuje dodatno lajšanje bolečin ali nadaljevanje lajšanja bolečin, lahko na novo mesto na koži zunanjega dela nadlahti ali prsi namestite nov sistem.
Troubleshooting
Odpravljanje motenj
Each IONSYS system is designed to deliver every on-demand dose of fentanyl over approximately 10 minutes.
Vsak sistem IONSYS je zasnovan tako, da dovaja posamezen odmerek fentanila na zahtevo v času približno 10 minut.
If a technical failure with a system is suspected, the staff member or patient should monitor both the illumination of the red LED and any audible signals (beeps) over the next dose.
Če sumite na tehnično napako v sistemu, bo moralo osebje ali sam bolnik v času dajanja naslednjega odmerka spremljati tako vklop rdeče LED kot vse morebitne zvočne signale (piske).
The table below represents the different error messages that may occur, together with the appropriate action to be taken:
V spodnji preglednici so navedena različna sporočila o napakah, ki se lahko pojavijo, skupaj z ustreznimi ukrepi, ki jih je treba uvesti:
Error Message Frequency 2 beeps repeated 8 times (approximately 15 seconds) and red LED turns off before 10 minutes 4 continuous beeps and red LED turns off before 10 minutes
Pogostnost signalov za napako 2 piska, ponovljena 8- krat (približno 15 sekund) in rdeča LED ugasne prej kot v 10 minutah 4 neprekinjeni piski in rdeča LED ugasne prej kot v 10 minutah Rdeča LED ne sveti
Action Up to 2 more attempts may be made to request new delivery.
Ukrep Še do dvakrat lahko poskusite dati nov odmerek.
If all attempts fail, the system should be removed and a new system applied to a new skin site.
Če bodo vsi poskusi neuspešni, sistem odstranite in namestite nov sistem na novo mesto na koži.
The system cannot be restarted.
Sistema ne boste mogli ponovno zagnati.
It should be removed and a new system applied to a new skin site.
Morate ga sneti in namestiti nov sistem na novo mesto na koži.
The system should be removed and a new system applied to a new skin site.
Sistem snemite in namestite novega na novo mesto na koži.
IONSYS should only be activated by the patient, to avoid potential overdosing.
4. 4 Posebna opozorila in previdnostni ukrepi
4 IONSYS should be restricted to hospital use only.
4 Sistem IONSYS sme aktivirati le sam bolnik, da preprečimo morebitno preveliko odmerjanje.
Oral ingestion of the fentanyl-containing gel may cause life-threatening hypoventilation or death.
Peroralno zaužitje gela, ki vsebuje fentanil, lahko povzroči smrtno nevarno hipoventilacijo ali smrt.
Do not touch the gel or allow gel to touch the mouth or other mucosal areas.
Ne dotikajte se gela in ne dovolite, da bi gel prišel v stik z vašimi usti ali z drugimi predeli sluznice.
A potentially dangerous amount of fentanyl remains in the IONSYS system after use.
Po uporabi ostane v sistemu IONSYS potencialno nevarna količina fentanila.
Please refer to section 6.6 for Special precautions for disposal.
Za navodila za ravnanje z zdravilom in odlaganje glejte poglavje 6. 6 Posebni varnostni ukrepi za odstranjevanje
Remove the IONSYS system before a magnetic resonance imaging (MRI) procedure, cardioversion, or defibrillation.
Sistem IONSYS morate sneti pred vsakim postopkom slikanja z magnetno resonanco (MRI – » magnetic resonance imaging «), kardioverzijo ali defibrilacijo.
The active substance in IONSYS is fentanyl which has a well known abuse potential.
Učinkovina v zdravilu IONSYS je fentanil, za katerega je znano, da ga je možno zlorabiti.
Physicians should evaluate patients for a history of drug abuse and follow such patients closely.
Zdravniki morajo oceniti bolnikovo zgodovino zlorabe drog in take bolnike pozorno spremljati.
Since IONSYS is indicated only for a short-term treatment the risks related to the dependence potential are not of concern.
Ker je zdravilo IONSYS indicirano samo za kratkotrajno uporabo, tveganje za razvoj odvisnosti ni veliko.
There was also no evidence of abuse of the system during the clinical trials.
Tudi med kliničnimi preskušanji ni bilo dokazov o zlorabi sistema.
As with all potent opioids, significant respiratory depression may occur with IONSYS; patients must be observed for these effects (see also Section 4.9).
Bolnike morate opazovati, da bi ugotovili te učinke (glejte tudi poglavje 4. 9).
The use of concomitant CNS-active medicinal products may increase the risk of respiratory depression (see Section 4.5).
Sočasna uporaba zdravil, ki delujejo na CŽS, lahko poveča tveganje za depresijo dihanja (glejte poglavje 4. 5).
In patients with chronic obstructive pulmonary disease or patients with conditions pre-disposing them to hypoventilation, more severe adverse reactions may be experienced.
Pri bolnikih s kronično obstruktivno pljučno boleznijo ali pri tistih s stanji, zaradi katerih so bolj nagnjeni k pojavu hipoventilacije, lahko nastopijo hujši neželeni učinki.
IONSYS should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention, such as those with evidence of increased intracranial pressure, impaired consciousness, or coma.
Sistema IONSYS ne smete uporabljati pri bolnikih, ki so lahko še posebej občutljivi na intrakranialne učinke zastajanja CO2 v telesu, na primer tistih, ki imajo znake povečanega intrakranialnega tlaka, motenj zavesti ali kome.
Opioids may obscure the clinical course of patients with head injury.
Opioidi lahko prikrijejo klinično sliko pri bolnikih s poškodbami glave.
IONSYS should be used with caution in patients with brain tumours.
Sistem IONSYS uporabljajte previdno tudi pri bolnikih z možganskimi tumorji.
Fentanyl may produce bradycardia or hypotension and should therefore be administered with caution to patients with bradyarrhythmias or any significant cardiovascular disease.
Fentanil lahko povzroči bradikardijo ali hipotenzijo in ga morate torej uporabljati previdno pri bolnikih z bradiaritmijami ali kakršnokoli pomembno srčnožilno boleznijo.
IONSYS should be used with caution in patients with paralytic ileus.
Sistem IONSYS morate uporabljati previdno pri bolnikih s paralitičnim ileusom.
Hepatic disease
Jetrne bolezni
Fentanyl is metabolized into inactive metabolites in the liver.
Fentanil se v jetrih presnovi v neaktivne presnovke.
Hepatic disease may delay elimination.
Jetrne bolezni lahko zavrejo izločanje zdravila.
Patients with hepatic impairment should be observed carefully for signs of fentanyl toxicity.
Bolnike z jetrno okvaro morate skrbno opazovati, da ugotovite morebitne znake toksičnosti fentanila.
Renal disease
Ledvične bolezni
Less than 10% of administered fentanyl is excreted unchanged by the kidney.
5 Manj kot 10% danega fentanila se izloči v nespremenjeni obliki preko ledvic.
Unlike morphine, no active fentanyl metabolites are eliminated by the kidney.
Za razliko od morfina pa se preko ledvice ne izločajo aktivni presnovki fentanila.
This may affect serum concentrations.
Podatki dobljeni z intravensko uporabo fentanila pri bolnikih z ledvično odpovedjo kažejo, da lahko dializa spremeni porazdelitveni volumen fentanila in s tem vpliva na njegovo serumsko koncentracijo.
If patients with renal impairment receive IONSYS, they should be observed carefully for signs of fentanyl toxicity.
Kadar bolniki z ledvično okvaro prejmejo zdravilo IONSYS, jih morate skrbno opazovati, da bi lahko ugotovili morebitne znake toksičnosti fentanila.
Limited data on pharmacokinetics, safety and efficacy are available for the use of IONSYS in patients > 75 years.
O uporabi sistema IONSYS bri bolnikih > 75 let je na voljo omejena količina podatkov o farmakokinetiki, varnosti in učinkovitosti.
Elderly patients should be observed carefully for signs of fentanyl toxicity.
Starejše bolnike morate skrbno opazovati, da bi lahko ugotovili morebitne znake toksičnosti fentanila.
Obese patients
Bolniki z močno povečano telesno maso
Efficacy and safety in patients with body mass index greater than 40 has not been established.
Učinkovitost in varnost pri bolnikih z indeksom telesne mase nad 40 še ni bila ugotovljena.
Hearing impairment
Okvara sluha
IONSYS should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system.
Sistem IONSYS morate uporabljati previdno pri bolnikih z okvarjenim sluhom, ki morda ne bodo mogli slišati zvočnih signalov sistema.
Thoracic/ chest and upper abdominal surgeries
Kirurški posegi v prsnem košu ali zgornjem delu trebuha
Only limited data are available in patients with thoracic/ chest and upper abdominal surgeries.
O bolnikih, ki so imeli kirurški poseg v prsnem košu ali zgornjem delu trebuha je na voljo le omejena količina podatkov.
IONSYS should therefore be used with caution in these patients.
Pri teh bolnikih je potrebna previdnost pri uporabi sistema IONSYS.
Cystic Fibrosis
Cistična fibroza
Efficacy and safety in patients with cystic fibrosis has not been established.
Učinkovitost in varnost pri bolnikih s cistično fibrozo še ni bila ugotovljena.
The safety of IONSYS has not been established in patients with American Society of Anesthesiologists (ASA) physical status classification IV.
Varnost sistema IONSYS še ni bila ugotovljena pri bolnikih s fizikalnim statusom IV po ASA (American Society of Anesthesiologists).
With each new IONSYS application the patient may use IONSYS more frequently than during the remainder of the 24 hour dosing period, due to a lower absorption of fentanyl from the system for the first few hours (see section 5.2).
Ker je absorpcija fentanila iz sistema v prvih nekaj urah manjša (glejte poglavje 5. 2), lahko bolnik sistem IONSYS ob vsaki novi namestitvi pogosteje uporabi, kot med preostankom 24- urnega obdobja odmerjanja.
Interaction with other medicinal products and other forms of interaction
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interaction studies have only been performed in adults.
Preskušanja medsebojnega delovanja so izvedli le pri odraslih.
The concomitant use of other central nervous system depressants, including other opioids, sedatives or hypnotics, general anaesthetics, phenothiazines, tranquilizers, skeletal muscle relaxants, sedating antihistamines, and alcoholic beverages, may produce additive depressant effects.
Sočasna uporaba drugih depresivov centralnega živčnega sistema, vključno z drugimi opioidi, sedativi in uspavali, splošnimi anestetiki, fenotiazini, trakvilanti, mišičnimi relaksanti, sedativnimi antihistaminiki in alkoholnimi pijačami, lahko povzroči dodatne depresivne učinke.
Therefore, the use of any of these medicinal products concomitantly with IONSYS requires special patient care and observation.
Nastopi lahko hipoventilacija, hipotenzija in globoka sedacija ali koma, zato je pri uporabi kateregakoli od teh zdravil sočasno s sistemom IONSYS potrebna posebna oskrba bolnika ter opazovanje.
Fentanyl, a high clearance active substance, is rapidly and extensively metabolised mainly by CYP3A4.
Fentanil, učinkovina z velikim očistkom, se hitro in obsežno presnovi predvsem s CYP3A4.
Itraconazole, a potent CYP3A4 inhibitor, at 200 mg/ day orally for 4 days had no significant effect on the pharmacokinetics of intravenous fentanyl.
Itrakonazol, ki je močan zaviralec CYP3A4 in so ga dajali v peroralnem odmerku 200 mg/ dan v času 4 dni, ni imel pomembnega učinka na farmakokinetiko intravensko danega fentanila.
Oral ritonavir, one of the most potent CYP3A4 inhibitors, reduced the clearance of intravenous fentanyl by two thirds.
Peroralno dan ritonavir, eden od najmočnejših zaviralcev CYP3A4, pa je zmanjšal očistek intravensko danega fentanila za kar dve tretjini.
The concomitant use of potent CYP3A4 inhibitors such as ritonavir with IONSYS may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse events, and may cause serious respiratory depression.
Sočasna uporaba močnih zaviralcev CYP3A4, kakršen je ritonavir, s sistemom IONSYS lahko vodi do povečanja plazemskih koncentracij fentanila, kar bi lahko povečalo
In this situation, special patient care and observation are appropriate.
V tem primeru je potrebna posebna oskrba bolnika ter opazovanje.
The concomitant use of ritonavir or other CYP3A4 inhibitors and IONSYS is not recommended unless the patient is closely monitored.
Sočasna uporaba ritonavira ali drugih zaviralcev CYP3A4 in sistema IONSYS ni priporočljiva, razen če bolnika skrbno spremljate.
6 IONSYS is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
IONSYS ni priporočljiv za uporabo pri bolnikih, ki so prejemali zaviralce monoamin- oksidaze (MAO) v zadnjih 14 dneh, ker so pri opioidnih analgetikih poročali o hudi in nepredvidljivi okrepitvi učinkov zaviralcev MAO.
Pregnancy and lactation
4. 6 Nosečnost in dojenje
IONSYS should not be used in pregnancy unless clearly necessary.
Sistema IONSYS ne smete uporabljati med nosečnostjo, razen če je nujno potrebno
Administration during childbirth is not recommended because fentanyl crosses the placenta and the foetal respiratory centre is sensitive to opiates.
Uporaba sistema med porodom ni priporočljiva, ker fentanil prehaja skozi posteljico, dihalni center ploda pa je občutljiv za opiate.
If IONSYS is administered, an antidote for the child should be readily available.
Če uporabljate sistem IONSYS, mora biti takoj na voljo antidot za otroka.
Following long-term treatment fentanyl may cause withdrawal in the newborn.
Dolgotrajno zdravljenje s fentanilom ima lahko za posledico odtegnitveni sindrom pri novorojenčkih.
Fentanyl is excreted into maternal milk.
Fentanil se izloča v materino mleko.
Breast-feeding is not recommended for 24 hours following removal of IONSYS.
Dojenje ni priporočljivo še 24 ur po odstranitvi sistema IONSYS.
Women of childbearing potential/ Fertility
Ženske v rodni dobi in plodnost
See section 5.3 (reproductive toxicology)
Glejte poglavje 5. 3 (vpliv na sposobnost razmnoževanja).
Effects on ability to drive and use machines
4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
IONSYS has major influence on the ability to drive and use machines.
IONSYS ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Fentanyl can cause dizziness and somnolence, therefore patients should only drive vehicles or operate heavy machinery if sufficient time has elapsed after the administration of IONSYS.
Fentanil lahko povzroči omotico in zaspanost, zato smejo bolniki voziti ali upravljati s težkimi stroji le, če je minilo dovolj časa od uporabe sistema IONSYS.
Undesirable effects
4. 8 Neželeni učinki
In controlled clinical studies, the safety of IONSYS 40 micrograms was evaluated in a total of 791 patients.
V kontroliranih kliničnih študijah so ovrednotili varnost sistema IONSYS 40 mikrogramov pri skupaj 791 bolnikih.
The most commonly reported adverse events were nausea, vomiting, headache and pruritus.
Najpogosteje prijavljeni neželeni dogodki so bili slabost, bruhanje, glavobol in pruritus.
These were mostly of mild to moderate severity.
Ti so bili po jakosti večinoma blagi do zmerni.
The following adverse reactions that are at least possibly related to treatment have been reported in the clinical trials; not all of these reactions have been uniformly attributed to IONSYS by the investigators, therefore causation cannot be established.
Raziskovalci pa vseh teh učinkov niso enotno pripisali uporabi sistema IONSYS, zato ni mogoče ugotoviti vzročnosti.
Very Common Undesirable Effects (> 1/ 10)
Zelo pogosti neželeni učinki (> 1/ 10)
Common Undesirable Effects (> 1/ 100 to < 1/ 10)
Pogosti neželeni učinki (> 1/ 100 do < 1/ 10)
Uncommon Undesirable Effects (> 1/ 1000 to < 1/ 100)
(> 1/ 1. 000 do < 1/ 100)
Dizziness Somnolence
omotica somnolenca
Agitation Abnormal dreams Anxiety Insomnia Hallucinations Depression Hypesthesia
vznemirjenost nenormalne sanje zaskrbljenost nespečnost halucinacije depresija hipestezija živčnost
Uncommon Undesirable Effects (> 1/ 1000 to < 1/ 100) Nervousness Tremor Vertigo
Občasni neželeni učinki (> 1/ 1. 000 do < 1/ 100) tremor vrtoglavica
Tachycardia Bradycardia Hypertension Migraine Syncope
tahikardija bradikardija hipertenzija migrena sinkopa
Myalgia Edema Hypocalcemia Hypoglycemia Hypokalemia
mialgija edem hipokalciemija hipoglikemija hipokaliemija
Apnea Hiccup Hypoventilation Dyspnea Lung disorder Cough increased Rhinitis
apneja kolcanje hipoventilacija dispneja pljučne bolezni poslabšanje kašlja rinitis
Constipation Flatulence
zaprtje napenjanje
Eructation Gastro-intestinal disorder Ileus Dry mouth Dyspepsia Anorexia
spahovanje prebavne motnje ileus suha usta dispepsija anoreksija
Rash Wound site inflammation edema
izpuščaj vnetje na mestu rane edem
Urinary retention
zastajanje seča
Oliguria Urination impaired
oligurija zmanjšano uriniranje
Headache, *ASRs - erythema
glavobol * ASR - eritem
*ASRs – itching, vesicles Fever
* ASR – srbenje, vezikule zvišana telesna temperatura
*ASRs– papules/ pustules, sweating, dry & flaky skin, burning Abdominal pain Back pain Pain Chills
* ASR – papule/ pustule, potenje, suha koža, ki se lušči, občutek pečenja trebušne bolečine bolečine v hrbtu bolečine mrzlica
*ASRs = application site reactions
* ASR = reakcije na mestu aplikacije
Overdose
Simptomi
The manifestations of fentanyl overdosage are an extension of its pharmacologic actions, the most serious effect being respiratory depression.
Tem ukrepom lahko sledi dajanje specifičnega antagonista opioidov, kakršen je nalokson.
8 Treatment
8 delovanje antagonista opioidov.
For management of respiratory depression, immediate countermeasures include removing the IONSYS system and physically or verbally stimulating the patient.
Razpolovna doba antagonista je lahko kratka, zato bo morda potrebno njegovo večkratno dajanje ali dajanje v neprekinjeni infuziji.
Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist.
Izničenje učinka narkotika lahko vodi do akutnega pojava bolečine in sproščanja kateholaminov.
If the clinical situation warrants, a patent airway should be established and maintained, possibly with an oropharyngeal airway or endotracheal tube and oxygen should be administered and respiration assisted or controlled, as appropriate.
Če to zahteva klinično stanje bolnika, vzpostavite in ohranjajte odprte dihalne poti, če je mogoče z uporabo orofaringealnega ali endotrahealnega tubusa, in bolniku dovajajte kisik ter po potrebi zagotovite asistirano ali nadzorovano ventilacijo.
Adequate body temperature and fluid intake should be maintained.
Ohranjajte ustrezno telesno temperaturo in vnos tekočin.
If severe or persistent hypotension occurs, hypovolemia should be considered and the condition should be managed with appropriate parenteral fluid therapy.
Če nastopi huda ali trdovratna hipotenzija, premislite, ali ima bolnik morda hipovolemijo in ga zdravite z ustrezno terapijo s parenteralnim dajanjem tekočin.
Opioid analgesics (phenylpiperidine derivative), ATC code:
Opioidni analgetiki (derivati fenilpiperidina), oznaka ATC:
Fentanyl is an opioid analgesic, interacting predominantly with the opioid μ -receptor.
Fentanil je opioidni analgetik, ki deluje predvsem na opioidne receptorje μ.
Its primary therapeutic actions are analgesia and sedation.
Njegova poglavitna terapevtska učinka sta analgezija in sedacija.